Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

NVP-BHG712

HY-13258

(NVP-BHG 712; NVP BHG 712)

NVP-BHG712

NVP-BHG712 Chemical Structure

NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.

Size Price Stock Quantity
10 mM * 1 mL in DMSO $92 In-stock
5 mg $83 In-stock
10 mg $165 In-stock
50 mg $820 In-stock
100 mg $1400 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €90 In-stock
5 mg €81 In-stock
10 mg €162 In-stock
50 mg €804 In-stock
100 mg €1372 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: NVP-BHG712
Cat. No.: HY-13258

NVP-BHG712 Data Sheet

  • View current batch:

    Purity: 99.82%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

    Pdf Version

    NMR

    Pdf Version

    LCMS

Customer View

Related Compound Libraries

Biological Activity of NVP-BHG712

NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c-Abl with IC50 of 0.395 μM, 1.266 μM and 1.667 μM, respectively.
IC50 value: 25 nM(EC50)
Target: EphB4 receptor;c-Raf; c-Src
in vitro: NVP-BHG712 treatment also dose dependently leads to the inhibition of RTK autophosphorylation in stable transfected A375 melanoma cells with EC50 of 25 nM and 4.2 μM for EphB4 and VEGFR2, respectively [1].
in vivo: In a growth factor-induced angiogenesis model, NVP-BHG712 (3 mg/kg, p.o) significantly suppresses VEGF stimulated tissue formation and vascularization by inhibiting EphB4 forward signaling. Furthermore, NVP-BHG712 (10 mg/kg/kg, p.o.) potently reverses VEGF enhanced tissue formation and vessel growth. NVP-BHG712 (3 mg/kg, p.o.) shows a long lasting exposure with concentrations around 10 μM in plasma as well as in lung and liver tissue for up to 8 hours, and thus results in a long lasting inhibition of EphB4 kinase activity in mice [1].

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 503.48 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C26H20F3N7O
CAS No 940310-85-0
Solvent & Solubility

10 mM in DMSO

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.9862 mL 9.9309 mL 19.8618 mL
5 mM 0.3972 mL 1.9862 mL 3.9724 mL
10 mM 0.1986 mL 0.9931 mL 1.9862 mL

References on NVP-BHG712

Inhibitor Kit

Related Ephrin Receptor Products

  • ALW-II-41-27

    ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor.

  • JI-101

    JI-101 is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor (beta) (PDGFR-(beta)), and ephrin type-B receptor 4 (EphB4). JI-101 inhibits angiogenesis, and subsequently tumor growth. [1]